Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

What Is the Timing and Role of Targeted Therapy in Metastatic Melanoma?

Cancer journal (Sudbury, Mass.) - 1 Jan 2024

Hadfield Matthew J, Sullivan Ryan J

Abstract excerpt

ABSTRACT: Melanoma is the most lethal cutaneous malignancy worldwide. The last 15 years have ushered in several regulatory approvals that have dramatically altered the landscape of treatment options for patients with melanoma. Many patients with melanoma harbor activating mutations in the BRAF proto-oncogene, a key component of the mitogen-activated protein kinase (MAPK) intracellular signaling pathway. Therapies...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to BRAF gene
Share to Immune Checkpoint Inhibitors
Share to Melanoma

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Molecular Targeted Therapy

Share to Mutation

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins B-raf

Share to Skin Neoplasms

Source

Identifiers

PMID: 38527261
DOI: 10.1097/PPO.0000000000000712

Genes

BRAF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

What Is the Timing and Role of Targeted Therapy in Metastatic Melanoma?PMID 38527261Read ↗

Frontline approach to metastatic BRAF-mutant melanoma diagnosis, molecular evaluation, and treatment choice.Semantic proximity Read ↗

Targeted and immunotherapies in BRAF mutant melanoma: where we stand and what to expect.Semantic proximity Read ↗

Identifying the optimum first-line therapy in BRAF-mutant metastatic melanoma.Semantic proximity Read ↗

Treating metastatic melanoma in 2014: what just happened and what is next?Semantic proximity Read ↗

Emerging targeted therapies for melanoma.Semantic proximity Read ↗

Immunotherapy in Melanoma: A Dynamic Frontier in Cancer Treatment : Author List.Semantic proximity Read ↗

How to treat BRAF mutant metastatic melanoma?Semantic proximity Read ↗

The potential of BRAF-targeted therapy combined with immunotherapy in melanoma.Semantic proximity Read ↗

The Current State of Molecular Testing in the BRAF-Mutated Melanoma LandscapeSemantic proximity Read ↗

Molecular Targeted Therapy Approaches for BRAF Wild-Type Melanoma.Semantic proximity Read ↗

BRAF plus MEK-targeted drugs: a new standard of treatment for BRAF-mutant advanced melanoma.Semantic proximity Read ↗

Beyond BRAF: where next for melanoma therapy?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.